A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026).

Hennessy MA, Cimino-Mathews A, Carter JM, Kachergus JM, Ma Y, Leal JP, Solnes LB, Abramson VG, Carey LA, Rimawi M, Specht J, Storniolo AM, Vaklavas C, Krop I, Winer E, Denbow R, Valero V, Wolff AC, Wahl RL, Huang CY, Stearns V, Thompson EA, Connolly RM